Post by marriott on Feb 11, 2018 0:45:04 GMT
Applied DNA Reports Fiscal First Quarter 2018 Financial Results
Company To Hold Conference Call and Webcast Today, Thursday, February 8, 2018 at 4:30 PM EST.
STONY BROOK, N.Y. - February 8, 2018 - Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), announced financial results for the fiscal 2018 first quarter ended December 31, 2017.
"We made significant progress in the first quarter on the execution of our growth strategy to expand our base of business in our core markets and broaden the application of our molecular tagging technology platform in adjacent markets, although our results reflect a slow start to the fiscal year," stated Dr. James A. Hayward, chairman, president and CEO. "During and subsequent to the end of the fiscal first quarter, we developed new, long-term revenue opportunities, including the expansion of our cotton business into international markets with our first sale of a DNA Transfer System to an overseas ginner, and secured a contract award from TheraCann that leverages our cotton expertise to better track cannabis and its derivatives. Through our synthetic fiber customer GHCL, we have also gained the attention of the largest integrated producer of polyester fiber and yarn in the world on our CertainT platform and, with the upcoming filing of our Drug Master File with the FDA, we can now pursue revenue opportunities with pharmaceutical companies in a much more vigorous manner.
"Looking ahead to the balance of fiscal 2018, the expansion of our cotton business into a major overseas cotton-producing region reflects the growing importance brands owners, retailers and manufacturers place on the origin and authenticity of their cotton-based products and the continued adoption of our proven molecular taggant technology for textiles. This, together with continued adoption of CertainT by the synthetic fiber market and the imminent entry into the cannabis, pharmaceuticals, and other adjacent market opportunities, give us reason for continued optimism for this fiscal year. We, therefore, are reaffirming our base revenue guidance for fiscal 2018 of $6.5 million with a majority of revenue to be generated in our fiscal third and fourth quarters that are our peak cotton quarters," concluded Dr. Hayward.
Fiscal First Quarter Financial Results:
• Revenues decreased 28% for the first quarter of fiscal 2018 to $648 thousand, compared with $903 thousand reported in the first quarter of fiscal 2017, and decreased 43% from the $1.1 million reported in the fourth fiscal quarter ended September 30, 2017. The year-over-year and quarter-over-quarter decrease in revenues resulted primarily from the timing of shipments and the recognition of deferred revenue related to our cotton contracts.
• Total operating expenses decreased to $3.5 million for the first fiscal quarter of 2018, compared with $4.6 million in the prior fiscal year's first quarter. This decrease is primarily attributable to a decrease in stock based compensation expense.
• Net loss for the quarter ended December 31, 2017 was $3.2 million, or $0.12 per share, compared with a net loss of $4.0 million, or $0.16 per share, for the quarter ended December 31, 2016 and a net loss of $2.9 million, or $0.10 per share for the quarter ended September 30, 2017.
• Excluding non-cash expenses, Adjusted EBITDA was negative $2.8 million for the quarter ended December 31, 2017 and $2.3 million for the same quarter in the prior fiscal year.
Recent Operational Highlights:
• On February 6, Applied DNA announced that it had generated successful initial results of the Company's ability to detect its taggant throughout all points in the legal cannabis supply chain. Applied DNA believes that its taggants will serve as a unique forensic identifier that becomes part of a blockchain transaction throughout the legal cannabis supply chain.
• On January 31, the Company announced the first international order of its patent-pending SigNature® T DNA Transfer system for an overseas cotton market. The system will be installed in Applied DNA's fiscal second quarter and in advance of expected orders for its molecular taggants for cotton.
• On January 29, Applied DNA announced its collaboration with its customer GHCL and GHCL supplier Reliance Industries Ltd. to launch CertainT® verified recycled PET bedding products at New York Home Fashions week. Reliance's involvement underscores growing awareness and interest in Applied DNA's CertainT supply chain authentication platform by synthetic fiber manufacturers.
• On January 25, the Company announced the signing of an initial two-year, $1 million contract with TheraCann International Benchmark Corporation for the integration of Applied DNA's SigNature molecular tagging and testing technology into TheraCann's blockchain-based, seed-to-sale Enterprise Resource Platform (ERP) for legal cannabis operations. Under the terms of the contract, the two companies have entered into a development and marketing agreement whereby the Company will develop the technologies necessary to tag and authenticate legal cannabis throughout the supply chain and seamlessly integrate tagging and authentication data into TheraCann's ERP and Blockchain platform.
• On January 23, Applied DNA announced the establishment of a Central DNA Testing Laboratory in Ahmedabad, India, to provide full forensic authentication services. The laboratory, scheduled to open on February 15, 2018, supports the Company's growing global textile business in the Asia-Pacific region with expansion capability for other supply chains present in the region, such as fertilizer and pharmaceuticals.
• On January 18, Applied DNA announced the introduction of a GeoTyping™ Beta Program for the month of February, to brands and retailers interested in identifying country-of-origin cases of cotton fiber substitution. The Company's high-resolution cotton GeoTyping assays are a complement to SigNature T® tagging and serves as a means to identify the source of cotton fiber substitution.
• On December 20, the Company entered into a securities purchase agreement with certain institutional investors to purchase an aggregate of 2,735,000 shares of common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering. The offering closed on December 22, 2017 with net proceeds of approximately $4.2 million, exclusive of warrant exercise proceeds. Applied DNA intends to use the net proceeds of the offering for working capital, capital expenditures, business development and research and development expenditures and the acquisitions of new technologies or businesses.